Contributor Disclosures for IgA Nephropathy

Role Name Disclosure Details Author  Mohammad Ilyas, MD, FAAP, Assistant Professor of Pediatrics, University of Florida College of Medicine; Consulting Staff, Department of Pediatrics, Section of Nephrology, Wolfson Children Hospital and Shands Hospital Jacksonville Nothing to disclose Details Coauthor  Richard Neiberger, MD, PhD, Director of Pediatric Renal Stone Disease Clinic, Associate Professor, Department of Pediatrics, Division of Nephrology, University of Florida College of Medicine and Shands Hospital Nothing to disclose Details Medical Editor  Deogracias Pena, MD, Medical Director of Dialysis, Department of Pediatrics, Cook Children's Medical Center; Clinical Associate Professor, Texas Tech University School of Medicine Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  Adrian Spitzer, MD, Professor, Department of Pediatrics, Albert Einstein College of Medicine; Director of NIH Training Program, Children's Hospital at Montefiore Medical Center Nothing to disclose Details CME Editor  Howard Trachtman, MD, Program Director, Pediatrics Research, Schneider Children's Hospital, Department of Pediatrics, Division of Nephrology, Professor, Albert Einstein College of Medicine Nothing to disclose Details Chief Editor  Craig B Langman, MD, The Isaac A Abt, MD, Professor of Kidney Diseases, Feinberg School of Medicine, Northwestern University; Division Head of Kidney Diseases, Children's Memorial Hospital, Chicago Amgen Abbott Altus Pharmaceuticals Genzyme Merck Details Contributor Disclosure Contributor: Contributor Disclosure: Mohammad Ilyas, Author  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Richard Neiberger, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Deogracias Pena, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Adrian Spitzer, Managing Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Howard Trachtman  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Craig B Langman  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Amgen Grant/research funds None   Abbott Honoraria Speaking and teaching   Altus Pharmaceuticals Grant/research funds None   Genzyme Grant/research funds None   Merck Grant/research funds None   Off label or investigational use of medication